1	Real-World Effectiveness of Live Attenuated vs. Inactivated Influenza Vaccines in Children
2 3 4	Vera Rigamonti (MSc) <sup>1</sup> , Vittorio Torri (MSc) <sup>2</sup> , Shaun K Morris (MD, MPH, FRCPC, Prof) <sup>3,4,5,6</sup> , Francesca Ieva (Prof) <sup>2,7</sup> , Carlo Giaquinto (Prof) <sup>8</sup> , Daniele Donà (MD, PhD) <sup>8</sup> , Costanza Di Chiara (MD, PhD) <sup>1,3,8*</sup> , Anna Cantarutti (PhD) <sup>1*</sup> on behalf of the CARICE study group
5	
6	*contributed as co-senior authors
7	A complete list of CARICE study group members appears in Appendix 1
8	
9	Affiliations:
10 11 12	1 Laboratory of Healthcare Research and Pharmacoepidemiology, Department of Statistic and Quantitative Methods, Division of Biostatistics, Epidemiology and Public Health, University of Milano-Bicocca, Milano, Italy
13 14	2 MOX – Modelling and Scientific Computing Lab, Department of Mathematics, Politecnico di Milano, Milano, Italy
15	3 Division of Infectious Diseases, The Hospital for Sick Children, Toronto, ON, Canada
16	4 Center for Global Child Health, The Hospital for Sick Children, Toronto, ON, Canada
17	5 Department of Pediatrics, Faculty of Medicine, University of Toronto, Toronto, ON, Canada
18 19	6 Division of Clinical Public Health and Centre for Vaccine Preventable Diseases, Dalla Lana School of Public Health, Toronto, ON, Canada
20	7 HDS - Health Data Science Centre, Human Technopole, Milano, Italy
21	8 Department of Women's and Children's Health, University of Padova, Padova, Italy
22	
23 24 25	Address correspondence to: Costanza Di Chiara MD, Division of Pediatric Infectious Diseases, Department for Women's and Children's Health, University of Padua, Italy. Via Giustiniani 3, Padua, Italy. Contact: Phone: 0498213585, E-mail: <a href="mailto:costanza.dichiara@phd.unipd.it">costanza.dichiara@phd.unipd.it</a>
26	
27	Short title: Live Attenuated Influenza Vaccine Effectiveness
28	
29 30 31	<b>Conflict of Interest Disclosures (includes financial disclosures):</b> The authors have indicated that they have neither potential conflicts of interest nor financial relationships relevant to the article to disclose.
32	
33 34 35 36	<b>Funding/Support:</b> This work is partially supported by CARICE (COVID-19 and Acute Respiratory Infections: the Clinical and Epidemiological changes in the pediatric population) project, which is funded by the Ministry of University and Research within the PRIN 2022 PNRR.

37 Abbreviations:

- 38 IIV, inactivated influenza vaccine
- 39 LAIV, live attenuated influenza vaccine
- 40 quadrivalent LAIV (LAIV-4)
- 41 ILI, influenza-like illness
- 42 FP, family pediatrician
- 43 VE, vaccine effectiveness
- 44 HR, hazard ratio
- 45 CI, confidence interval
- 46 PPIP, special professional commitment service

47

48 **Article Summary:** A retrospective population-based cohort analysis showing moderate 49 effectiveness of live attenuated influenza vaccines (LAIVs) in preventing influenza/influenza-like-50 illness in Italian children.

51

### 52 What's Known on This Subject

There is conflicting evidence on the effectiveness of the quadrivalent live attenuated influenza
 vaccine LAIV (LAIV-4) in the pediatric population.

55

## 56 What This Study Adds

57 This population-based study assesses the effectiveness of LAIVs against influenza/influenza-like

<sup>58</sup> illness (ILI) among children in Italy in the post-COVID-19 influenza seasons using real-world data.

59 Our findings document moderate protection provided by LAIVs against influenza/ILI in the 2022-60 2023 and 2023-2024 seasons.

61

62

## 63 **Contributors Statement Page**

- Dr. Vera Rigamonti performed the statistical analysis, interpreted the results, and drafted the initialmanuscript;
- 66 Dr. Vittorio Torri conceptualized and designed the artificial intelligence algorithms;
- 67 Dr. Daniele Donà contributed to data interpretation;

Drs Anna Cantarutti and Costanza Di Chiara, designed the study, contributed to the analysis plan,
 interpreted the results, supervised the project, and contributed to the manuscript writing;

Profs. Shaun K Morris, Francesca Ieva, and Carlo Giaquinto interpreted the results and critically
 reviewed the manuscript for important intellectual content.

All authors reviewed, edited, and approved the final version of the manuscript, authorized its submission for publication, and agree to be accountable for all aspects of the work.

## 74 *Abstract* (word count=249/250)

**Background and objectives:** Quadrivalent live attenuated influenza vaccines (LAIV-4) offer an alternative to inactivated influenza vaccines (IIV) for children aged 2-17 years, but data on their comparative effectiveness are limited. This study assessed vaccination rates and real-world effectiveness of LAIV-4 and IIV in preventing influenza and influenza-like illness (ILI) in Italian

- effectiveness of LAIV-4 and IIV in preventing influenza and influenza-like illness (ILI) in Italia
   children during the 2022-2023 and 2023-2024 seasons.
- 80 Methods: We conducted a population-based cohort study of children aged 2-14 years from
- 81 September 2022 to April 2024, using data from Pedianet, a pediatric primary care database of
- 82 anonymized records from family pediatricians. Children vaccinated with LAIV-4 or IIV were
- 83 compared to unvaccinated children. The primary outcome was any first influenza or ILI episode.
- 84 Monthly vaccination incidence rates per 1,000 person-months were calculated for each vaccine
- type. Hazard ratios (HRs) and their 95% confidence intervals (CIs) for vaccine effectiveness (VE)
  were estimated using adjusted mixed-effects Cox models.
- **Results:** A total of 65,545 (472,173 person-months) and 72,377 (527,348 person-months) children
- were included for the 2022-2023 and 2023-2024 seasons, respectively. Vaccination rates were
- 12.71 and 12.85 per 1,000 person-months, respectively. Compared to unvaccinated children, LAIV-
- 4 had an overall effectiveness of 43% (95% CI, 32%-53%), while IIV effectiveness was 54% (95%
- 91 CI, 46%-61%). In 2022-2023, LAIV-4 (38% [95% CI, 12%-56%]) and IIV (49% [95% CI, 37%-
- 92 58%]) had comparable effectiveness. In 2023-2024, LAIV-4 (40% [95% CI, 25%-52%]) was
- 93 slightly less effective than IIV (58% [95% CI, 44%-68%])(p=0.048).
- 94 Conclusions: An overall moderate, comparable effectiveness of LAIV-4 and IIV in preventing
- 95 influenza/ILI among Italian children was observed.
- 96
- 97 Keywords: influenza, influenza vaccine, vaccine effectiveness, real-world data, population-based
- 98 study, children
- 99
- 100 WORD count: 2593

## 101 Background

102	Influenza causes seasonal epidemics and occasional pandemics, leading to significant
103	morbidity and mortality worldwide [1]. While children and adolescents generally face a lower risk
104	of severe illness compared to infants and the elderly [2], they remain vulnerable to severe infections
105	[3-5]. Moreover, they play a crucial role in the spread of the virus in the communities [3-8].
106	Vaccination is the most cost-effective strategy to prevent seasonal influenza, reducing
107	morbidity and reducing community transmission, thus protecting vulnerable groups [9,10].
108	However, the prevalence of children vaccinated against influenza remains low and, in Italy, ranged
109	from 7% to 15% during the flu seasons from 2009 to 2018 [10].
110	Inactivated influenza vaccines (IIV) have been the cornerstone of influenza prevention for decades.
111	Live attenuated influenza vaccines (LAIV), administered as a nasal spray, have only recently started
112	being extensively used as an alternative to intramuscular IIV for children aged 2-17 years. Both
113	vaccines are currently quadrivalent and updated annually based on national and international
114	recommendations [11].
115	In Italy, influenza vaccination is offered free of charge to all children aged six months to six years,
116	although it is recommended for all pediatric age groups [12]. Two-dose influenza vaccination is
117	recommended in children younger than nine years who haven't received previous influenza
118	vaccinations, regardless of the type of vaccine (LAIV or IIV); one-dose influenza vaccination is
119	recommended for other children [12].
120	The immune responses elicited by these two vaccine types differ significantly, potentially
121	impacting their effectiveness [13]. IIVs induce strong serum antibody responses, particularly IgG,
122	but have limited capacity to induce mucosal IgA or T-cell responses. Conversely, LAIVs elicit a
123	broader immune response, encompassing cellular, humoral, and mucosal components [14]. This
124	broader response better mimics natural infection and may offer enhanced protection against a wider
125	range of influenza strains, including those not closely matched to the vaccine, as well as reducing
126	transmission [14].

Studies on the effectiveness of LAIV and IIV in children show inconsistent results [15-18].
Some comparative studies suggest superior efficacy of LAIV over IIV [3,19-21]. However,
observational studies indicate mixed effectiveness of LAIVs depending on the setting and
circulating strain [22-25].
This population-based cohort study aimed to describe the administration rate of LAIV-4 and
IIV and assess the real-world effectiveness of LAIV-4 vs IIV in preventing influenza and influenza-
like illness (ILI) episodes among Italian children and adolescents during the 2022-2023 and 2023-
2024 influenza seasons when LAIV-4 became available in Italy.
Materials and Methods
Setting
Publicly funded primary healthcare services for children in Italy are delivered free of charge
by individual Family Pediatricians (FPs) within the National Health System. This study utilized
data from Pedianet (http://www.pedianet.it), a well-established electronic health record database
specifically designed for pediatric care covering around 4% of the annual pediatric population [26].
Pedianet encompasses data from over 200 FPs across Italy who utilize the Junior Bit® software in
their practices, providing a representative coverage of the Italian pediatric population [26].
This comprehensive database includes anonymized patient-level information, including
demographics, growth parameters, diagnoses and symptoms (both ICD-9-CM coded and free text
entries), medication prescriptions, and disease-based healthcare exemptions — which cover the
costs of essential medical services such as diagnostics, treatments, and medications required for
managing chronic conditions— and vaccination history.
In Italy, influenza vaccination is administered by FPs who participate voluntarily in the
influenza vaccination program. These FPs receive reimbursement through the Special Professional
Commitment Services (PPIPs) registry. Participation in the influenza vaccination program is not

mandatory for FPs in Italy. We defined FPs as participants if they vaccinated at least 1.5% of theirpatients [10].

Data anonymization is performed in accordance with Italian regulations. Each anonymized record is assigned a unique numerical identifier. The data is then transmitted monthly to a centralized database located in Padua, Italy, for validation purposes. Inclusion in the Pedianet database is voluntary, and parents/legal guardians must provide general consent for their children's anonymized data to be stored and used for research purposes. The Internal Scientific Committee of Società Serivizi Telematici Srl, the legal owner of Pedianet granted ethical approval of the study and access to the database.

161

#### 162 *Study design and study cohort criteria*

We conducted a retrospective observational cohort study on children aged 2 to 14 years 163 164 enrolled in the Pedianet database and followed by FPs adhering to the influenza vaccination 165 program during the observation period from September 1, 2022, to April 30, 2024. We worked on 166 two subsequent flu seasons; the first went from September 1, 2022 to April 30, 2023, and the 167 second from September 1, 2023 to April 30, 2024. To ensure complete data on exposure, outcomes, 168 and covariates, we only included children who adhered to the recommended well-child visit 169 schedule with their FP, aligning with established protocols outlined in previous research [27], and 170 with at least one year of follow-up before entry into the cohort.

171 Children who recorded any influenza/ILI episode from the day of influenza vaccination (day172 0) to 14 days post-vaccination were excluded.

173

#### 174 *Exposure to influenza vaccine*

Children were classified as exposed or unexposed to influenza vaccination for each season
included in the study. Exposed children were further classified into those exposed to LAIV-4 and
those exposed to IIV, based on whether they received a single dose of each respective vaccine type.

178 Unexposed children were considered the reference group.

179

198

#### 180 *Outcome and definitions*

181 The primary outcome of the study was any influenza/ILI episode. Only the first seasonal 182 influenza/ILI episode for each child was considered, as repeated influenza episodes within the same 183 season are rare (1.6%), and influenza itself may confer immunity against future infections [28]. 184 An influenza/ILI episode was defined based on an artificial intelligence algorithm, which 185 used any reported clinical diagnosis of influenza (ICD-9-CM code: 487, 487.0, 487.1, 487.8), 186 and/or free text of medical charts. A tailored Natural Language Processing algorithm to identify 187 influenza/ILI cases from free text data was defined and validated on manually annotated data. The 188 algorithm analyzed both the free text fields of the Pedianet database and, for patients admitted to 189 hospitals in the Veneto region, the text of their discharge letters. These two sources were found to 190 be complementary in identifying patients with influenza (Supplementary materials – Description 191 of influenza artificial intelligence algorithms). 192 *Covariates* 193 194 Covariates used for confounding adjustment included demographic variables (sex, age at the 195 start of each influenza season, Italian region of birth, and deprivation index [29]), influenza 196 vaccination status, number of influenza/ILI episodes, antibiotic therapies, and primary care visits in 197 the epidemiological season preceding the season of interest, and comorbidities.

199 healthcare exemption for chronic complex condition (i.e., cystic fibrosis, diabetes, chronic

200 obstructive pulmonary disease, and asthma), immunodeficiency or immunosuppressive therapy,

201 neurological and neurocognitive conditions (including Trisomy 21), prematurity (less than 37 weeks

Children were classified as having comorbidity if they had at least one disease-based

202 of gestation), renal failure, congenital cardiac disease (including heart failure), or chronic liver

203 conditions (Supplementary materials – Table S1).

204

## 205 Statistical analysis

206	Administration rates of influenza vaccination stratified by vaccine type (LAIV-4 or IIV)
207	were calculated per 1,000 person-months.
208	Descriptive statistics were provided, and the chi-squared test was used to assess differences
209	between the groups of children who were unvaccinated, exposed to LAIV-4, and exposed to IIV.
210	Mixed-effect Cox proportional-hazards models were used to assess the effectiveness of
211	LAIV-4 and IIV compared to unexposed children in preventing influenza/ILI, considering the FP as
212	a random effect. Hazard ratios (HRs) and their corresponding 95% confidence intervals (CIs) were
213	independently estimated for each vaccine type relative to the unvaccinated group. Vaccine
214	effectiveness (VE) was then calculated as $VE = (1-HR)x100$ .
215	Influenza vaccine exposure was considered a time-varying covariate to avoid immortal time
216	bias. All models were adjusted for covariates of interest (sex, age at the start of each influenza
217	season, Italian region of birth, deprivation index, comorbidities, and influenza vaccination status,
218	number of influenza/ILI episodes, antibiotic therapies, and primary care visits in the
219	epidemiological season preceding the season of interest) and for correlation within children who
220	contributed to more than one influenza season. Follow-up began on September 1st and ended upon
221	death, migration, transfer to an FP outside the Pedianet network, occurrence of the incident
222	outcome, or the end of the study period, which coincided with the end of the season evaluated
223	(April 30).
224	Homogeneity between the LAIV-4 and IIV effectiveness was tested using the chi-squared
225	test [30].
226	Finally, sensitivity analyses were performed stratifying the main models by influenza season
227	and replicating the main analysis on children aged 2-5 years.
228	All data analyses were performed using SAS statistical software, version 14.1 (SAS, College
229	Station, TX, USA). Hypothesis tests were two-sided with a type I error of 0.05.

250	2	3	0
-----	---	---	---

### 231 Results

- 232 Study cohort characteristics
- A total of 65,545 (472,173 person-months) and 72,377 (527,348 person-months) children were included in the study for the 2022-2023 and 2023-2024 influenza seasons, respectively. The
- inclusion and exclusion flowchart is shown in **Figure 1**.
- 236Table 1 (Table S2 and S3) presents the sociodemographic and clinical variables of the
- study population. Overall, this shows that 125,142 children were unvaccinated, 5,270 were exposed
- to LAIV-4, and 7,510 were exposed to IIV. Exposed children were younger, mostly born in
- southern Italy, and had fewer comorbidities. Comparing LAIV-4-exposed and IIV-exposed

children, those in the LAIV-4 group were younger and had fewer comorbidities.

241

242 Influenza vaccine administration rates by season

A total of 6,003 (12.71 per 1,000 person-months) and 6,777 (12.85 per 1,000 person-

months) children were vaccinated for influenza in the 2022-2023 and 2023-2024 seasons,

245 respectively.

In the 2022-2023 influenza season, LAIV-4 administration rate (3.56 per 1,000 person-months) was

lower than that of IIV (9.15 per 1,000 person-months). Interestingly, in the 2023-2024 season, the

- administration rate of LAIV-4 (6.80 per 1,000 person-months) appeared to converge with that of
- 249 IIV (6.05 per 1,000 person-months) (**Figure 2**).

- 251 Effectiveness of LAIV-4 and IIV
- **Figure 3** shows the effectiveness of LAIV-4 and IIV against influenza/ILI. Overall,
- compared to unexposed children, the effectiveness of LAIV-4 was 43% (95% CI, 32%-53%), and

254	the effectiveness of IIV was 54% (95% CI, 46%-61%). There was no significant difference between
255	the effectiveness of LAIV-4 and IIV in preventing influenza/ILI (p-value = $0.095$ ).
256	To better understand the effectiveness of LAIV-4 and IIV against different influenza virus
257	variants, we evaluated the effectiveness of both vaccines against influenza/ILI separately for the
258	2022-2023 and 2023-2024 seasons. In the 2022-2023 season, LAIV-4 (38% [95% CI, 12%-56%])
259	and IIV (49% [95% CI, 37%-58%]) showed comparable effectiveness (p-value = 0.374). However,
260	in the 2023-2024 season, a slightly significantly lower effectiveness of LAIV-4 (40% [95% CI,
261	25%-52%]) compared to IIV (58% [95% CI, 44%-68%]) was observed (p-value = 0.048) (Figure
262	3).
263	To better evaluate the impact of age on VE, we replicated the main analysis on children
264	aged 2-5 years. The effectiveness of LAIV-4 against influenza/ILI (46% [95% CI, 32%-57%]) was
265	comparable to that of IIV (55% [95% CI, 43%-64%]) (p-value = $0.266$ ).
266	
267	Discussion
268	This nationwide study aimed to investigate the real-world effectiveness of the LAIV-4 vs
269	IIV among children and adolescents across Italy. To the best of our knowledge, this is the first
270	population-based study assessing the effectiveness of LAIV-4 against influenza/ILI in the Italian
271	pediatric population using real-world data. It is also the first study in Italy to develop a Natural
272	Language Processing algorithm for the identification of patients with influenza/ILI from free text
273	records.
274	Our results strengthen and expand the evidence from other studies evaluating LAIV-4
275	effectiveness in the pediatric population [21,31]. We found moderate protection by LAIV-4 against
276	influenza/ILI episodes, with VE of 38% and 40% in the 2022-2023 and 2023-2024 seasons,
277	respectively. Previous studies evaluated the protection of LAIV-4 against influenza, observing a VE
278	ranging from 0% to 50% in seasons 2014-2015 through 2018-2019 [17,23,24,32]. Our study found

similar protection against influenza/ILI in the pediatric population compared to these results.

тv

280 Differences in LAIV-4 effectiveness across studies might be due to several factors, including the 281 age and immune status of recipients and antigenic similarity between the vaccine and circulating 282 strains [21-24,33]. Moreover, differences in influenza VE could also be attributed to varying 283 exposure and outcome definitions among studies [31]. 284 We observed similar effectiveness of LAIV-4 and IIV in preventing influenza/ILI in 285 children, in accordance with findings from previous studies [17]. However, a trend emerged when 286 analyzing by influenza season. Although VE was confirmed for both LAIV-4 and IIV in the two 287 study seasons, during the 2023-2024 season, IIV appeared to offer slightly greater protection 288 compared to LAIV-4. Previous analyses have yielded conflicting results due to variations in study 289 populations and influenza strains. While some evidence showed a reduced effectiveness of LAIV 290 compared to IIV against influenza A/H1N1pdm09 in children aged 2 to 17 years during the 2013-291 2014 and 2015–2016 seasons [14], other research on healthy children aged 6 to 59 months indicated 292 that LAIV were more effective than IIV during the 2004-2005 influenza season [34]. 293 The study also documented an increase in LAIV-4 administration rates between the 2022-294 2023 and 2023-2024 seasons during the implementation of a new type of vaccine in Italy. These 295 results predict a promising higher influenza vaccine uptake among children and adolescents, driven 296 by vaccination campaigns based on less invasive vaccine administration. This aligns with previous 297 research showing caregivers were more likely to accept nasal spray vaccines than injectable ones 298 [35-36].

This study has several strengths. The use of data from Pedianet, a large population-based dataset, allowed us to assess the real-world effectiveness of LAIV-4 in Italian children. While randomized clinical trials remain the gold standard for demonstrating vaccine safety and efficacy, real-world evidence has become crucial for ongoing VE monitoring, given the influenza virus's dynamics. Furthermore, due to the Italian-wide coverage of Pedianet, which collects all sociodemographic and clinical information, we obtained complete medical information for enrolled children, thus accounting for the impact of influenza/ILI episodes and influenza vaccination in the

previous season. Moreover, the high quality of data on the influenza vaccination provided by FPs
adhering to the influenza vaccination program, which reimbursed FPs for every dose of
administered influenza vaccine minimizing exposure misclassification.

309 However, this study has several limitations. Children receiving influenza vaccination may 310 differ from unvaccinated children in some unmeasured covariates, which results in residual 311 confounding. The exclusion of children followed by FPs not adhering to the influenza vaccination 312 program could also affect the study. Moreover, Pedianet only includes influenza vaccinations 313 registered by FPs, leading to a small underreporting of vaccine coverage. Additionally, since 314 influenza/ILI cases were defined clinically rather than confirmed by laboratory testing, outcome 315 misclassification cannot be excluded, especially given that in Italy, the 2022–2023 and 2023–2024 316 influenza seasons coincided with similar surges in RSV and COVID-19. Furthermore, due to the 317 lack of hospitalization data, we were unable to assess the effectiveness of IIV and LAIV-4 against 318 hospitalization and severe outcomes, which are the primary goals for vaccinating children. Lastly, 319 the 2022–2024 period was characterized by low pre-existing influenza immunity in the population 320 following the COVID-19 pandemic. While this setting provided a unique opportunity for a more 321 direct assessment of real-world influenza VE, it also raises questions about the generalizability of 322 our findings to seasons with higher pre-existing immunity. However, several studies suggest that 323 pre-existing immunity may not prevent infection but does reduce illness severity [37], supporting 324 that the absence of pre-existing immunity should not significantly affect the generalizability of our 325 results.

In conclusion, this population-based analysis provides real-world evidence on the moderate, comparable effectiveness of LAIV-4 and IIV against influenza/ILI among children across Italy. Further studies are needed to confirm our findings in future influenza seasons and investigate the effectiveness of LAIV-4 in preventing severe influenza/ILI in children and adolescents. Research focusing on the effectiveness of the LAIV-4 in the pediatric population is crucial for optimizing

331 pediatric influenza vaccination campaigns to increase vaccination acceptance and uptake among

332 children.

#### 333 Acknowledgments

334 The authors thank all the family paediatricians collaborating in Pedianet. Eva Alfieri, Michela Alfiero Bordigato, Angelo Alongi, Biagio Amoroso, Rosaria Ancarola, Barbara Andreola, 335 336 Giampaolo Anese, Roberta Angelini, Maria Grazia Apostolo, Giovanna Argo, Giovanni Avarello, 337 Lucia Azzoni, Maria Carolina Barbazza, Patrizia Barbieri, Gabriele Belluzzi, Eleonora Benetti, 338 Filippo Biasci, Franca Boe, Stefano Bollettini, Francesco Bonaiuto, Anna Maria Bontempelli, Matteo Bonza, Sara Bozzetto, Andrea Bruna, Ivana Brusaterra, Massimo Caccini, Laura Calì, Sonia 339 340 Camposilvan, Laura Cantalupi, Luigi Cantarutti, Chiara Cardarelli, Giovanna Carli, Sylvia 341 Carnazza, Massimo Castaldo, Stefano Castelli, Monica Cavedagni, Giuseppe Egidio Cera, Chiara 342 Chillemi, Francesca Cichello, Giuseppe Cicione, Carla Ciscato, Mariangela Clerici Schoeller, 343 Samuele Cocchiola, Giuseppe Collacciani, Valeria Conte, Roberta Corro', Rosaria Costagliola, Nicola Costanzo, Sandra Cozzani, Giancarlo Cuboni, Giorgia Curia, Caterina D'alia, Vito 344 345 Francesco D'Amanti, Antonio D'Avino, Roberto De Clara, Lorenzo De Giovanni, Annamaria De 346 Marchi, Gigliola Del Ponte, Tiziana Di Giampietro, Giuseppe Di Mauro, Giuseppe Di Santo, Piero 347 Di Saverio, Mattea Dieli, Marco Dolci, Mattia Doria, Dania El Mazloum, Maria Carmen Fadda, 348 Pietro Falco, Mario Fama, Marco Faraci, Maria Immacolata Farina, Tania Favilli, Mariagrazia 349 Federico, Michele Felice, Maurizio Ferraiuolo, Michele Ferretti, Mauro Gabriele Ferretti, Paolo 350 Forcina, Patrizia Foti, Luisa Freo, Ezio Frison, Fabrizio Fusco, Giovanni Gallo, Roberto Gallo, 351 Andrea Galvagno, Alberta Gentili, Pierfrancesco Gentilucci, Giuliana Giampaolo, Francesco 352 Gianfredi, Isabella Giuseppin, Laura Gnesi, Costantino Gobbi, Renza Granzon, Mauro Grelloni, 353 Mirco Grugnetti, Antonina Isca, Urania Elisabetta Lagrasta, Maria Rosaria Letta, Giuseppe Lietti, 354 Cinzia Lista, Ricciardo Lucantonio, Francesco Luise, Enrico Marano, Francesca Marine, Lorenzo 355 Mariniello, Gabriella Marostica, Sergio Masotti, Stefano Meneghetti, Massimo Milani, Stella 356 Vittoria Milone, Donatella Moggia, Angela Maria Monteleone, Pierangela Mussinu, Anna Naccari, 357 Immacolata Naso, Flavia Nicoloso, Cristina Novarini, Laura Maria Olimpi, Riccardo Ongaro, Maria 358 Maddalena Palma, Angela Pasinato, Andrea Passarella, Pasquale Pazzola, Monica Perin, Danilo 359 Perri, Silvana Rosa Pescosolido, Giovanni Petrazzuoli, Giuseppe Petrotto, Patrizia Picco, 360 Ambrogina Pirola, Lorena Pisanello, Daniele Pittarello, Elena Porro, Antonino Puma, Maria Paola 361 Puocci, Andrea Righetti, Rosaria Rizzari, Cristiano Rosafio, Paolo Rosas, Bruno Ruffato, Lucia Ruggieri, Annamaria Ruscitti, Annarita Russo, Pietro Salamone, Daniela Sambugaro, Luigi Saretta, 362 Vittoria Sarno, Valentina Savio, Nico Maria Sciolla, Rossella Semenzato, Paolo Senesi, Carla 363 Silvan, Giorgia Soldà, Valter Spanevello, Sabrina Spedale, Francesco Speranza, Sara Stefani, 364 365 Francesco Storelli, Paolo Tambaro, Giacomo Toffol, Gabriele Tonelli, Silvia Tulone, Angelo Giuseppe Tummarello, Cristina Vallongo, Sergio Venditti, Maria Grazia Vitale, Concetta Volpe, 366 367 Francesco Paolo Volpe, Aldo Vozzi, Giulia Zanon, Maria Luisa Zuccolo. 368

- 371 *References*
- 1. Centers for Disease Control and Prevention. Disease burden of influenza. 2018.
- Wang X, Li Y, O'Brien KL, et al. Global burden of respiratory infections associated with
   seasonal influenza in children under 5 years in 2018: a systematic review and modelling study.
   Lancet Glob Health 2020; 8: e497–510.
- Smith KJ, Raviotta JM, DePasse JV, Brown ST, Shim E, Patricia Nowalk M, et al. Cost
   effectiveness of influenza vaccine choices in children aged 2–8 years in the U.S. Am J Prev
   Med. 2016;50(5):600–8. https://doi.org/10.1016/j.amepre.2015.12.010.
- Gregg M, Blackhouse G, Loeb M, Goeree R. Economic evaluation of an influenza
   immunization strategy of healthy children. Int J Technol Assess Health Care. 2014;30(4):394–9.
   https://doi.org/10.1017/S0266462314000397.
- Pebody RG, Green HK, Andrews N, Boddington NL, Zhao H, Yonova I, et al. Uptake and
   impact of vaccinating school age children against influenza during a season with circulation of
   drifted influenza a and B strains, England, 2014/15. Eurosurveillance. 2015;20:39.
   https://doi.org/10.2807/1560-7917.ES.2015.20.39.30029.
- Grijalva CG, Zhu Y, Simonsen L, Mitchel E, Griffin MR. The Population Impact of a Large
   School-Based Influenza Vaccination Campaign. Poon LLM, editor. PLoS One.
   2010;5(11):e15097.
- 389 7. King JC. A pilot study of the effectiveness of a school-based influenza vaccination program.
   390 Pediatrics. 2005;116(6):e868–73. https://doi.org/10.1542/peds.2005-1301.
- King JC, Lichenstein R, Cummings GE, Magder LS. Impact of influenza vaccination of schoolchildren on medical outcomes among all residents of Maryland. Vaccine. 2010 Nov;28(49):7737–42. https://doi.org/10.1016/j.vaccine.2010.09.064.
- Tsang TK, Fang VJ, Ip DKM, et al. Indirect protection from vaccinating children against influenza in households. Nat Commun 2019; 10: 106.
- 10. Cantarutti A, Barbieri E, Didonè F, Scamarcia A, Giaquinto C, Corrao G. Influenza Vaccination
   Effectiveness in Paediatric 'Healthy' Patients: A Population-Based Study in Italy. Vaccines
   (Basel). 2022 Apr 10;10(4):582. doi: 10.3390/vaccines10040582.
- 11. Centers for Disease Control and Prevention (CDC). Key Facts About Influenza (Flu). Available
   at: CDC Influenza.
- 401 12. Ministero della salute. Direzione generale della prevenzione sanitaria. Circolare 21 aprile 2023.
   402 Prevenzione e controllo dell'influenza: raccomandazioni per la stagione 2023-2024. Published
   403 on April 21, 2023. Accessed on March 20, 2024. Available at:
- 403 on April 21, 2023. Accessed on March 20, 2024. Available at:
  404 https://www.salute.gov.it/portale/news/p3\_2\_1\_1\_1.jsp?lingua=italiano&menu=notizie&p=dal
  405 ministero&id=6229
- 406 13. Mohn KG, Smith I, Sjursen H, Cox RJ. Immune responses after live attenuated influenza
  407 vaccination. Hum Vaccin Immunother. 2018 Mar 4;14(3):571-578. doi:
- 408 10.1080/21645515.2017.1377376. Epub 2018 Jan 3. PMID: 28933664; PMCID: PMC5861782.
- 409 14. Hoft DF, Babusis E, Worku S, et al. Live and inactivated influenza vaccines induce similar
  410 humoral responses, but only live vaccines induce diverse T-cell responses in young children. J
  411 Infect Dis 2011;204: 845–53.
- 412 15. Chung, J. R., Flannery, B., Ambrose, C. S., Bégué, R. E., Caspard, H., DeMarcus, L., Fowlkes,
  413 A. L., Kersellius, G., Steffens, A., Fry, A. M., Influenza Clinical Investigation for Children
  414 Study Team, Influenza Incidence Surveillance Project, & US Influenza Vaccine Effectiveness
- Network (2019). Live Attenuated and Inactivated Influenza Vaccine Effectiveness. Pediatrics,
  143(2), e20182094. https://doi.org/10.1542/peds.2018-2094.
- 16. Caspard H, Gaglani M, Clipper L, et al. Effectiveness of live attenuated influenza vaccine and inactivated influenza vaccine in children 2-17 years of age in 2013-2014 in the United States.
- 419 Vaccine. 2016;34(1):77-82. doi:10.1016/j.vaccine.2015.11.010.

17. Flannery B. Influenza vaccine effectiveness, including LAIV vs IIV in children and adolescents, 420 US Flu VE Network, 2015-16.https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-421 422 2016-06/influenza-05-flannery.pdf. 423 18. Buchan SA, Booth S, Scott AN, et al. Effectiveness of Live Attenuated vs Inactivated Influenza 424 Vaccines in Children During the 2012-2013 Through 2015-2016 Influenza Seasons in Alberta, Canada: A Canadian Immunization Research Network (CIRN) Study. JAMA Pediatr. 425 2018;172(9):e181514. doi:10.1001/jamapediatrics.2018.1514. 426 19. Minozzi S, Lytras T, Gianola S, et al. Comparative efficacy and safety of vaccines to prevent 427 428 seasonal influenza: a systematic review and network meta-analysis. EClinicalMedicine 2022;46: 429 101331. 430 20. Jefferson T, Rivetti A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2018; 2: CD004879. 431 21. Shim E, Brown ST, DePasse J, Nowalk MP, Raviotta JM, Smith KJ, et al. Cost effectiveness of 432 influenza vaccine for U.S. children. Am J Prev Med. 2016 Sep;51(3):309-17. 433 434 https://doi.org/10.1016/j.amepre.2016.02.027. 22. Kildegaard H, Lund LC, Pottegård A, Stensballe LG. Effectiveness of the quadrivalent live 435 436 attenuated influenza vaccine against influenza-related hospitalisations and morbidity among children aged 2 to 6 years in Denmark: a nationwide cohort study emulating a target trial. 437 438 Lancet Child Adolesc Health. 2023 Dec;7(12):852-862. doi: 10.1016/S2352-4642(23)00225-0. 439 Epub 2023 Oct 25. PMID: 37898144. 23. Boddington NL, Pearson I, Whitaker H, Mangtani P, Pebody RG. Effectiveness of influenza 440 vaccination in preventing hospitalization due to influenza in children: a systematic review and 441 meta-analysis. Clin Infect Dis 2021; 73: 1722–32. 442 24. Baum U, Kulathinal S, Auranen K, Nohynek H. Effectiveness of 2 influenza vaccines in 443 nationwide cohorts of Finnish 2-year-old children in the seasons 2015-2016 through 2017-2018. 444 Clin Infect Dis 2020; 71: e255-61. 445 25. Pebody R, Djennad A, Ellis J, et al. End of season influenza vaccine effectiveness in adults and 446 447 children in the United Kingdom in 2017/18. Euro Surveill 2019; 24: 1800488. 448 26. Cantarutti A, Gaguinto C. Pedianet database. In: Sturkenboom M, Schink T, editors. Databases 449 for pharmacoepidemiological research. Springer series on epidemiology and public health. 450 Springer International Publishing (2021). p. 159–64. doi: 10.1007/978-3-030-51455-6 13. 27. Cantarutti A, Barbiellini Amidei C, Valsecchi C, et al. Association of treated and untreated 451 452 gastroesophageal reflux disease in the first year of life with the subsequent development of 453 asthma. Int J Environ Res Public Health. 2021;18(18):9633. 454 28. Möst J, Redlberger-Fritz M, Weiss G. Multiple Influenza Virus Infections in 4 Consecutive Epidemiological Seasons: A Retrospective Study in Children and Adolescents. Open Forum 455 456 Infect Dis. 2019 Apr 23;6(6):ofz195. doi: 10.1093/ofid/ofz195. 457 29. Batzella E, Cantarutti A, Caranci N, Giaquinto C, Barbiellini Amidei C, Canova C. The 458 Association Between Pediatric COVID-19 Vaccination and Socioeconomic Position: Nested 459 Case-Control Study From the Pedianet Veneto Cohort. JMIR Public Health Surveill. 2023 Feb 460 1;9:e44234. doi: 10.2196/44234. PMID: 36645419; PMCID: PMC9897308. 30. Newman, S.C. Biostatistical Methods in Epidemiology; Wiley Series in Probability and 461 462 Statistics; JohnWiley & Sons: Hoboken, NJ, USA, 2002. 463 31. Sridhar S, Brokstad KA, Cox RJ. Influenza Vaccination Strategies: Comparing Inactivated and Live Attenuated Influenza Vaccines. Vaccines (Basel). 2015 Apr 24;3(2):373-89. doi: 464 10.3390/vaccines3020373. PMID: 26343192; PMCID: PMC4494344. 465 32. Boddington NL, Mangtani P, Zhao H, et al. Live-attenuated influenza vaccine effectiveness 466 against hospitalization in children aged 2-6 years, the first three seasons of the childhood 467 influenza vaccination program in England, 2013/14-2015/16. Influenza Other Respir Viruses 468 469 2022; 16: 897-905.

- 470 33. Krishnan A, Dar L, Saha S, Narayan VV, Kumar R, Kumar R, Amarchand R, Dhakad S, Chokker R, Choudekar A, Gopal G, Choudhary A, Potdar V, Chadha M, Lafond KE, Lindstrom 471 S, Widdowson MA, Jain S. Efficacy of live attenuated and inactivated influenza vaccines 472 473 among children in rural India: A 2-year, randomized, triple-blind, placebo-controlled trial. PLoS 474 Med. 2021 Apr 29;18(4):e1003609. doi: 10.1371/journal.pmed.1003609. PMID: 33914729; 475 PMCID: PMC8118535. 34. Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, Kemble G, Connor 476 EM; CAIV-T Comparative Efficacy Study Group. Live attenuated versus inactivated influenza 477 vaccine in infants and young children. N Engl J Med. 2007 Feb 15:356(7):685-96. doi: 478
- 479 10.1056/NEJMoa065368. Erratum in: N Engl J Med. 2007 Mar 22;356(12):1283. PMID:
  480 17301299.
  - 35. Marien AG, Hochart A, Lagrée M, Diallo D, Martinot A, Dubos F. Parental acceptance of an
    intranasal vaccine: Example of influenza vaccine. Arch Pediatr. 2019 Feb;26(2):71-74. doi:
    10.1016/j.arcped.2018.11.002. Epub 2019 Jan 15. PMID: 30658873.
  - 36. Rodgers L, Pabst LJ, Chaves SS. Increasing uptake of live attenuated influenza vaccine among
    children in the United States, 2008-2014. Vaccine. 2015 Jan 1;33(1):22-4. doi:
  - 486 10.1016/j.vaccine.2014.11.006. Epub 2014 Nov 17. PMID: 25448098; PMCID: PMC5845854.
  - 487 37. Patel, M. M., York, I. A., Monto, A. S., Thompson, M. G., & Fry, A. M. (2021). Immune-
  - 488 mediated attenuation of influenza illness after infection: opportunities and challenges. *The*
  - 489 *Lancet. Microbe*, 2(12), e715–e725. https://doi.org/10.1016/S2666-5247(21)00180-4

- 490 Legend of Figures
- **Figure 1.** Flowchart of the study cohort. Pedianet dataset 2010-2024.

children

- 492
- **Figure 2.** Monthly Administration Rates (AR) per 1,000 person-months of influenza vaccination
- among children in Italy by vaccine type.
- 495
- 496 Figure 3. Comparison between LAIV-4 and IIV vaccine effectiveness in preventing influenza/ILI

in

497 in


Italy.

# 498 *Table*

**Table 1.** Children sociodemographic and clinical characteristics by exposure.

	Unexposed	LAIV-4-exposed	IIV-exposed	P-value	P_voluo
	(N = 125,142)	(N = 5,270)	(N = 7,510)	unexposed vs exposed (both LAIV-4 and IIV)*	P-value LAIV-4 vs. IIV*
Sex					
Male	64,439 (51.49%)	2,724 (51.69%)	3,937 (52.42%)	0.2866	0.4131
Female	60,703 (48.51%)	2,546 (48.31%)	3,573 (47.58%)		
Age					
2-5 years	32,011 (25.58%)	3,034 (57.57%)	2,757 (36.71%)	. 0001	0001
6-10 years	51,181 (40.90%)	1,754 (33.28%)	3,214 (42.80%)	<.0001	<.0001
11-14 years	41,950 (33.52%)	482 (9.15%)	1,539 (20.49%)		
Region of birth in Italy					
North	83,518 (66.74%)	2,067 (39.22%)	3,857 (51.36%)	.0001	
Center	18,546 (14.82%)	752 (14.27%)	1,752 (23.33%)	<.0001	<.0001
South and islands	23,078 (18.44%)	2,451 (46.51%)	1,901 (25.31%)		
Deprivation index					
Low	42,872 (34.26%)	1,949 (36.98%)	2,740 (36.48%)	0.001	<.0001
High	59,161 (47.28%)	2,720 (51.51%)	3,565 (47.47%)	<.0001	
Missing	23,109 (18.47%)	601 (11.40%)	1,205 (16.05%)		
Comorbidity					
None	119,922 (95.83%)	4,909 (93.15%)	6,772 (90.17%)	<.0001	<.0001
At least one	5,220 (4.17%)	361 (6.85%)	738 (9.83%)		
Influenza vaccination status in the previous season				< 0001	< 0001
Unvaccinated	121,040 (96.72%)	2,026 (38.44%)	2,106 (28.04%)	<.0001	<.0001
Vaccinated	4,102 (3.28%)	3,244 (61.65%)	5,404 (71.96%)		
Influenza/ILI episode(s) in the previous season					
0	120,250 (96.09%)	5,058 (95.98%)	7,226 (96.22%)	0.7772	0.4872
>=1	4,892 (3.91%)	212 (4.02%)	284 (3.78%)		
Drug prescription(s) in the previous season					
0	91,634 (73.22%)	2,130 (40.42%)	4,306 (57.34%)	<.0001	<.0001
1-2	26,039 (20.81%)	1,967 (37.32%)	2,259 (30.08%)		
>=3	7,469 (5.67%)	1,173 (22.26%)	945 (12.58%)		
Specialistic visit(s) in the previous season				<.0001	0.0011
0-7	106,415 (85.04%)	3,013 (57.17%)	4,510 (60.05%)	<.0001	0.0011
>=8	18,727 (14.96%)	2,257 (42.83%)	3,000 (39.95%)		


500 \* Chi-squared test.




 $\frac{1}{2}$  9,309 children were excluded from the 2022/2023 cohort as they were only followed during the 2023/2024 influenza season and 31,114 children were excluded from the 2023/2024 cohort as they were only followed during the 2022/2023 influenza season

\* PPIPs, Special Professional Commitment Services

\*\* FP, family pediatrician





\* HRs were adjusted for sex, age at the start of each influenza season, Italian region of birth, deprivation index, comorbidities, and influenza vaccination status, number of influenza/ILI episodes, antibiotic therapies, and primary care visits in the epidemiological season preceding the season of interest.